Given the tolerability issues associated with the currently applicable—although last issued in 2007—treatment guidelines for NTM lung disease, how do you sequence and titrate therapy in patients you commit to anti-infective treatment?

Given the tolerability issues associated with the currently applicable—although last issued in 2007—treatment guidelines for NTM lung disease, how do you sequence and titrate therapy in patients you commit to anti-infective treatment?

Given the tolerability issues associated with the currently applicable—although last issued in 2007­—treatment guidelines for NTM lung disease, how do you sequence and titrate therapy in patients you commit to anti-infective treatment?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Antonio Catanzaro, MD

Antonio Catanzaro, MD

Professor of Medicine
Previously, Director, Tuberculosis Control
Division of Pulmonary, Critical Care, and Sleep Medicine
UC San Diego School of Medicine
San Diego, California